Purpose of Review

To highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity.

Recent Findings

Obesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established.

Summary

The evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.

中文翻译：

---

超越减肥：额外的好处可以指导抗肥胖药物的选择

审查目的

强调已获批准和即将上市的中枢作用抗肥胖药物的额外益处，不仅关注最常见的代谢和心血管影响，还关注其较少探索的临床益处和缺点，以便为临床医生提供一种工具更全面的肥胖药物管理。

最近的发现

肥胖在世界范围内越来越普遍，并已成为医疗保健系统和社会面临的挑战。预期寿命缩短和心脏代谢并发症是这种复杂疾病的部分后果。最近对肥胖病理生理学的深入了解导致了几个有前途的药理学靶点的开发，因此更有效的药物即将出现。拥有更广泛治疗范围的观点增加了个性化治疗的机会。这主要有可能利用长期使用抗肥胖药物来实现安全、有效和可持续的减肥，并同时解决已经确定的肥胖并发症/合并症。

概括

抗肥胖药物可用性的不断发展以及对其对肥胖并发症的附加影响的了解不断增加，将使临床医生能够进入精准医学的新时代。